Research Advances in the Treatment of B-Cell Acute Lymphoblastic Leukemia Based on Surface Antigen Expression --Review.
10.19746/j.cnki.issn.1009-2137.2021.02.055
- Author:
Yan SU
1
;
Qing-Song YIN
2
Author Information
1. Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China.
2. Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China,E-mail：jnyinqingsong@163.com.
- Publication Type:Review
- MeSH:
Adult;
Antigens, CD19;
Antigens, Surface;
B-Lymphocytes;
Burkitt Lymphoma;
Child;
Humans;
Immunotherapy, Adoptive;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*;
Receptors, Antigen, T-Cell
- From:
Journal of Experimental Hematology
2021;29(2):648-652
- CountryChina
- Language:Chinese
-
Abstract:
B-cell acute lymphoblastic leukemia (B-ALL) is a common malignant tumor in hematopoietic system. Although the remission rate of the patients with adult B-ALL is similar to those with childhood B-ALL, the rate of long-term disease-free survival (DFS) rate is significantly lower, once recurrence, the remission rate of routine chemotherapy is low and the prognosis is so poor. Based on the expression of tumor cell surface antigens(such as CD19, CD20 and CD22), the specific monoclonal antibodies, bispecific antibodies and chimeric antigen receptor T cells (CAR-T), and other targeted immunotherapy can greatly improve the efficacy of B-ALL patients, especially for patients with relapse and refractory. In this review, the progress of immunotherapy against B-ALL cell surface antigen is summarized briefly.
